Literature DB >> 24089657

Natural killer T cell based Immunotherapy.

Priyanka B Subrahmanyam1, Wenji Sun, James E East, Junxin Li, Tonya J Webb.   

Abstract

Natural killer T (NKT) cells play an important immunoregulatory role and are thought to bridge the innate and adaptive immune responses. Following activation through cognate interactions with lipid antigen presented in the context of CD1d molecules, NKT cells rapidly produce a plethora of cytokines and can also mediate cytotoxicity. Due to their potent effector functions, extensive research has been performed to increase our understanding on how to effectively modulate these cells. In fact, NKT cell agonists have been used as vaccine adjuvants to enhance antigen specific T and B cell responses to infections and malignancy. In this review, we will focus on recent advances in NKT cell-based vaccination strategies. Given the role that NKT cells play in autoimmune disease, infectious diseases, cancer, transplant immunology and dermatology, it is important to understand how to effectively guide their effector functions in order to develop novel immunotherapeutic strategies.

Entities:  

Keywords:  CD1d; NKT cells; vaccines

Year:  2012        PMID: 24089657      PMCID: PMC3786600          DOI: 10.4172/2157-7560.1000144

Source DB:  PubMed          Journal:  J Vaccines Vaccin


  140 in total

Review 1.  NKT cells: what's in a name?

Authors:  Dale I Godfrey; H Robson MacDonald; Mitchell Kronenberg; Mark J Smyth; Luc Van Kaer
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

2.  Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer.

Authors:  Tonya J Webb; Xiangming Li; Robert L Giuntoli; Pablo H H Lopez; Christoph Heuser; Ronald L Schnaar; Moriya Tsuji; Christian Kurts; Mathias Oelke; Jonathan P Schneck
Journal:  Cancer Res       Date:  2012-05-30       Impact factor: 12.701

3.  Viral evasion of antigen presentation: not just for peptides anymore.

Authors:  Luc Van Kaer; Sebastian Joyce
Journal:  Nat Immunol       Date:  2006-08       Impact factor: 25.606

Review 4.  CD1 antigen presentation: how it works.

Authors:  Duarte C Barral; Michael B Brenner
Journal:  Nat Rev Immunol       Date:  2007-12       Impact factor: 53.106

5.  Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells.

Authors:  T Kawano; J Cui; Y Koezuka; I Toura; Y Kaneko; H Sato; E Kondo; M Harada; H Koseki; T Nakayama; Y Tanaka; M Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

6.  A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.

Authors:  Shinichiro Motohashi; Aki Ishikawa; Eiichi Ishikawa; Mizuto Otsuji; Toshihiko Iizasa; Hideki Hanaoka; Naomi Shimizu; Shigetoshi Horiguchi; Yoshitaka Okamoto; Shin-ichiro Fujii; Masaru Taniguchi; Takehiko Fujisawa; Toshinori Nakayama
Journal:  Clin Cancer Res       Date:  2006-10-06       Impact factor: 12.531

7.  TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells.

Authors:  M Nieda; A Nicol; Y Koezuka; A Kikuchi; N Lapteva; Y Tanaka; K Tokunaga; K Suzuki; N Kayagaki; H Yagita; H Hirai; T Juji
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

8.  An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.

Authors:  Yeonseok Chung; Hong Qin; Chang-Yuil Kang; Sanghee Kim; Larry W Kwak; Chen Dong
Journal:  Blood       Date:  2007-06-20       Impact factor: 22.113

9.  Reduction in CD1d expression on dendritic cells and macrophages by an acute virus infection.

Authors:  Yinling Lin; Tonya J Roberts; Philip M Spence; Randy R Brutkiewicz
Journal:  J Leukoc Biol       Date:  2004-11-17       Impact factor: 4.962

10.  Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.

Authors:  David H Chang; Keren Osman; John Connolly; Anjli Kukreja; Joseph Krasovsky; Maggi Pack; Aisha Hutchinson; Matthew Geller; Nancy Liu; Rebecca Annable; Jennifer Shay; Kelly Kirchhoff; Nobusuke Nishi; Yoshitaka Ando; Kunihiko Hayashi; Hani Hassoun; Ralph M Steinman; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2005-05-02       Impact factor: 14.307

View more
  2 in total

1.  Bcl-xL regulates CD1d-mediated antigen presentation to NKT cells by altering CD1d trafficking through the endocytic pathway.

Authors:  Priyanka B Subrahmanyam; Gregory B Carey; Tonya J Webb
Journal:  J Immunol       Date:  2014-07-28       Impact factor: 5.422

2.  Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer.

Authors:  Eun Jeong Won; Jae Kyun Ju; Young-Nan Cho; Hye-Mi Jin; Ki-Jeong Park; Tae-Jong Kim; Yong-Soo Kwon; Hae Jin Kee; Jung-Chul Kim; Seung-Jung Kee; Yong-Wook Park
Journal:  Oncotarget       Date:  2016-11-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.